简介:目的探讨脐带血干细胞治疗失代偿期肝硬化患者的安全性及对肝功能的改善作用.方法选择失代偿期肝硬化患者52例,随机分为治疗组25例和对照组27例.对照组行护肝治疗,治疗组在此基础上经股动脉插管至肝固有动脉注入脐带血干细胞治疗.治疗后第2周、4周和8周检测血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)、凝血酶原时间(PT)和白蛋白(ALB)水平变化.同时观察临床症状的改善情况及术后的不良反应.结果治疗后第3天治疗组全部患者(100%)乏力、纳差症状改善,而对照组只有1例(4.0%)改善,两组间差异有显著性(P〈0.05);治疗后8wk,治疗组和对照组血清ALB水平分别为35.2±8.5g/L和25.8±7.8g/L,具有显著性差异P〈0.05),两组PTA分别为45.7±10.3%和37.9±11.8%,差异有显著性(P〈0.05);血清ALT、AST、TBIL在两组间变化不明显.随访两组AFP水平未见明显差异,未发现严重的不良反应及并发症.结论脐带血干细胞治疗失代偿期肝硬化患者有一定的疗效及安全性.
简介:目的观察肝硬化患者血清肿瘤标志物CAl25的变化与腹水的关系,以探讨其升高在肝硬化中的临床意义。方法以40例健康对照组及82例住院的肝硬化病人为研究对象,检测其全部血清及部分腹水(10例)CAl25水平。结果肝硬化组血清CAl25水平显著高于正常对照组,其中肝硬化组男女无性别差异,腹水组血清CAl25显著高于无腹水组,大量腹水者显著高于中少量腹水者,腹水中CAl25浓度高于血清浓度,相关性分析显示血清CAl25与Child分级、总胆红素水平呈正相关,与白蛋白、白/球比值呈负相关。结论血清CAl25在肝硬化时可明显升高,在腹水患者更显著,是诊断有无腹水的一个敏感指标。
简介:AIM:Toevaluatetheefficacyofthe14-dmoxifloxacinbasedtripletherapyforthesecond-lineeradicationofHelicobacterpylori(H.pylori)infection.METHODS:Between2011and2013,weconductedaretrospectivereviewofthemedicalrecordsof160patientswhohadexperiencedfailureoftheirfirst-lineprotonpumpinhibitor-basederadicationtherapyandsubsequentlyreceivedthemoxifloxacin-basedtripletherapyasasecond-lineeradicationtreatmentregimen.Thepatientswhoweretreatedwiththemoxifloxacinbasedtripletherapy(oral20mgrabeprazoleb.i.d.,1000mgamoxicillinb.i.d.,and400mgmoxifloxacinq.d.)for7dwereassignedtotheRAM-7group(n=79)whilethosewhotookthemfor14dayswereassignedtoRAM-14group(n=81).Theeradicationratesforbothgroupsweredeterminedbyintentionto-treat(ITT)andper-protocol(PP)analyses.ITTanalysiscomparedthetreatmentgroupsasoriginallyallocatedwhilethePPanalysisincludingonlythosepatientswhohadcompletedthetreatmentasoriginallyallocated.SuccessfuleradicationtherapyforH.pyloriinfectionwasdefinedasthedocumentationofanegative13C-ureabreathtest4wkaftertheendoftheeradicationtreatment.RESULTS:TheoverallITTeradicationratewas76.2%(122/160).ThefinalITTeradicationrateswere70.8%(56/79;95%CI:63.3%-77.1%)intheRAM-7groupand81.4%(66/81;95%CI:74.6%-88.3%)intheRAM-14group(P=0.034).TheoverallPPeradicationratewas84.1%(122/145),andthefinalPPeradicationrateswere77.7%(56/72;95%CI:70.2%-85.3%)intheRAM-7groupand90.4%(66/73;95%CI:82.8%-98.1%)intheRAM-14group(P=0.017).TheH.pylori-eradicationratesintheRAM-14groupweresignificantlyhighercomparedwiththatoftheRAM-7groupaccordingtoboththeITT(P=0.034)andthePPanalyses(P=0.017).Bothgroupsexhibitedgoodtreatmentcompliance(RAM-7/RAM-14group:100%/100%).Theadverseeventrateswere19.4%(14/72)and20.5%(15/73)intheRAM-7andRAM-14groups,respectively(P=0.441).Adverseeventsoccurredin14
简介:AIM:Toinvestigatetheefficacyofneoadjuvantchemoradiotherapy(NACRT)forresectabilityoflocallyadvancedgastriccancer(LAGC).METHODS:BetweenNovember2007andJanuary2014,29patientswithLAGC(clinicallyT3withdistalesophagusinvasion/T4orbulkyregionalnodemetastasis)thatweretreatedwithNACRTfollowedbyD2gastrectomywereincludedinthisstudy.ResectabilitywasevaluatedwithradiologicandendoscopicexamsbeforeandafterNACRT.Usingthreedimensionalconformalradiotherapy,patientsreceived45Gy,withadailydoseof1.8Gy.Theentiretumorextentandtheregionalmetastaticlymphnodeswereincludedinthegrosstumorvolume.PatientspresentingwitharesectabletumorafterNACRTreceivedatotalorsubtotalgastrectomywithD2dissection.ThepathologictumorresponsewasevaluatedusingJapaneseGastricCancerAssociationhistologicevaluationcriteria.PostoperativemorbiditywasevaluatedusingtheNationalCancerInstitute-CommonTerminologyCriteriaforAdverseEventsversion4.0.Overallsurvival(OS)andprogression-freesurvival(PFS)rateswereestimatedusingaKaplan-Meieranalysisandcomparedusingthelog-ranktest.RESULTS:Allpatientswereassessedasunresectablecases.Twenty-fourpatients(24/29;82.8%)showedLAGConpositronemissiontomography-computedtomography(CT)andcontrast-enhancedCT,whereasfourpatients(4/29;13.8%)withvagueinvasionorabutmenttoanadjacentorganunderwentdiagnosticlaparoscopy.Onepatient(1/29;3.4%),initiallyassessedasaresectablecase,underwentan'openandclosure'afterthetumorwasfoundtobeunresectable.Abutmenttoanadjacentorgan(34.5%)wasthemostcommonreasonforNACRT.TheclinicalresponserateonemonthafterNACRTwas44.8%.AfterNACRT,69%(20/29)ofpatientshadaresectabletumor.Ofthe20patientswitharesectabletumor,18patients(62.1%)underwentaD2gastrectomy.TheR0resectionratewas94.4%andtwopatients(2/18;11.1%)showedacompleteresponse.Themedianfollow-updurationwas13.5mo.Theone-yearOSandPFS
简介:AIM:ToinvestigatetheroleoftheoverexpressionofB7-H3inapoptosisincolorectalcancercelllinesandtheunderlyingmolecularmechanisms.METHODS:SW620cellsthathighlyoverexpressedB7-H3(SW620-B7-H3-EGFP)andHCT8cellsstablytransfectedwithB7-H3shRNA(HCT8-shB7-H3)werepreviouslyconstructedinourlaboratory.CellstransfectedwithpIRES2-EGFPwereusedasnegativecontrols(SW620-NCandHCT8-NC).Real-timePCRandwesternblottinganalysiswereusedtodetectthemRNAandproteinexpressionsoftheapoptosisregulatorproteinsBcl-2,Bcl-xlandBax.Acellproliferationassaywasusedtoevaluatethesurvivalrateanddrugsensitivityofthecells.Theeffectofdrugresistancewasdetectedbyacellcycleassay.Activecaspase-3westernblottingwasusedtoreflecttheanti-apoptoticabilityofcells.WesternblottingwasalsoperformedtodeterminetheexpressionofproteinsassociatedwiththeJak2-STAT3signalingpathwayandtheapoptosisregulatorproteinsafterthetreatmentwithAG490,aJak2specificinhibitor,inB7-H3overexpressingcells.ThedatawereanalyzedbyGraphPadPrism6usinganon-pairedt-test.RESULTS:WhetherbyoverexpressioninSW620cellsordownregulationinHCT8,B7-H3significantlyaffectedtheexpressionofanti-andpro-apoptoticproteins,atboththetranscriptionalandtranslationallevels,comparedwiththenegativecontrol(P<0.05).AcellproliferationassayrevealedthatB7-H3overexpressionincreasedthedrugresistanceofcellsandresultedinahighersurvivalrate(P<0.05).Inaddition,theresultsofcellcycleandactivecaspase-3westernblottingprovedthatB7-H3overexpressioninhibitedapoptosisincolorectalcancercelllines(P<0.05).B7-H3overexpressionimprovedJak2andSTAT3phosphorylationand,inturn,increasedtheexpressionofthedownstreamanti-apoptoticproteinsB-cellCLL/lymphoma2(Bcl-2)andBcl-xl,basedonwesternblotting(P<0.05).AftertreatingB7-H3overexpressingcellswiththeJak2-specificinhibitorAG490,thephosphorylationofJak2andSTAT3,andtheexp
简介:目的研究探讨幽门螺杆菌(Hp)感染与肝硬化高氨血症的关系。方法对60例肝硬化病人进行抗Hp治疗,观察治疗前后血氨浓度的变化。结果2001-03/2003-06收住的肝硬化病人60例,Hp感染阳性42例(A组),占61.0%,阴性者18例(B组),占39.0%。Hp阳性者血氨为151.0±36.5μmol/L,阴性者血氨为121.3±37.6μmol/L,两者有显著差异(P〈0.01)。Hp阴性者在治疗后血氨水平无显著性下降(P〉0.05)。结论在Hp阳性的肝硬化病人中,血氨水平的升高与Hp感染有关,根治Hp后可以降低血氨的浓度,对防止肝性脑病的发生可能有一定的临床意义。
简介:目的观察早期胃癌组织中GTP酶激活蛋白SH3功能区结合蛋白G3BP1和G3BP2的表达变化并探讨其意义。方法选择早期胃癌组织89例和正常对照组织35例,采用免疫组织化学方法检测两组G3BP1蛋白和G3BP2蛋白的表达情况。结果早期胃癌组和正常组G3BP1的阳性率分别为87.64%和60.00%,G3BP2阳性率分别为86.51%和54.28%,两组比较差异有统计学意义(P=0.000,0.000);早期胃癌G3BP1和G3BP2的表达均与幽门螺杆菌感染相关(P=0.000);早期胃癌组织中G3BP1与G3BP2表达呈正相关(rs=0.252,P=0.017)。结论早期胃癌组织中G3BP1和G3BP2呈高表达,可能与幽门螺杆菌感染紧密相关,两指标异常表达可能在早期胃癌的发生和发展中起重要作用。
简介:AIM:Toevaluatetheroleofsurvivinandcaspase-3inapoptosisofgastriccarcinoma,aswellasinprognosisofpatientswithgastriccarcinoma.METHODS:Expressionsofsurvivinandcaspase-3wereinvestigatedimmunohistochemicallyin80gastriccarcinomapatientswithoutahistoryofchemo-radiationtherapy.TumorcellapoptosiswasexaminedbyTUNELmethod.RESULTS:Immunohistochemicalanalysisshowedthatsurvivinexpressionwaspositivein61of80patients(76%)withgastriccarcinoma.Incontrast,noexpressionofsurvivininadjacentnormaltissueswasdetected.Expressionlevelofcaspase-3washigherinnormaltissuesthanincarcinoma.Patientswithhigherexpressionofsurvivinhadworsehistologicalgradesandpathologicalstages.Expressionofcaspase-3wassignificantlyassociatedwithhistologicalstages,butnotwiththepathologicalstages.Althoughsurvivinexpressionincarcinomawasnotinverselyrelatedtocaspase-3,patientswithsurvivin(-)andcaspase-3(+)hadthemaximumapoptosisindex.CONCLUSION:Expressionlevelofsurvivinwasassociatedwithhistologicalgradesandpathologicalstagesofthetumor,indicatingthatsurvivinmaybeapoorprognosisfactorforgastriccarcinoma.Unlikecaspase-3,survivin(anapoptosisinhibitor)canmarkedlyinhibittheapoptosisoftumorcells.
简介:背景:维生素D受体(VDR)属于类固醇激素受体超家族,参与细胞增殖、分化、凋亡以及免疫应答等多种生物学过程,在多种恶性肿瘤中呈低表达。目的:探讨VDR在结直肠癌中的表达及其调控机制。方法:收集2010年2月-2012年12月上海交通大学医学院附属仁济医院收治的结直肠癌患者30例,以免疫组化法检测癌组织和相应癌旁非癌组织标本的VDR表达情况。从基因表达汇编(GEO)数据库中提取224例结直肠癌患者的临床资料,分析其癌组织VDR表达与患者临床病理特征和生存期的关系。采用组蛋白-赖氨酸N-甲基转移酶EZH2-siRNA或5-氮杂胞嘧啶核苷(5-AZA)处理人结肠癌细胞株HCT116和SW620,以实时PCR检测VDR表达水平,以甲基化特异性PCR(MSP)检测VDR启动子区甲基化水平。结果:结直肠癌患者癌组织VDR阳性表达率显著低于癌旁非癌组织(26.7%对70.0%,P〈0.001)。结直肠癌组织VDR表达与肿瘤组织学分期、远处转移、脉管转移、淋巴结转移呈负相关(P〈0.05);VDR高表达者生存期显著长于低表达者(P=0.032)。与转染对照-siRNA相比,HCT116、SW620细胞转染EZH2-siRNA后,EZH2mRNA表达水平和VDR启动子区甲基化水平均显著降低(P〈0.05),VDRmRNA表达水平显著升高(P〈0.05)。5-AZA处理HCT116、SW620细胞后,VDR启动子区甲基化水平较阴性对照组显著降低(P〈0.05),VDRmRNA表达水平显著升高(P〈0.05)。结论:结直肠癌中VDR表达下调且与患者预后呈正相关。VDR在结直肠癌中的转录抑制受组蛋白甲基化和DNA甲基化共同调控。
简介:背景:Gankyrin是一个含锚蛋白重复序列的原癌蛋白,其高表达参与了多种恶性肿瘤的发生、发展进程。目的:探讨下调gankyrin表达对胃癌细胞增殖能力的影响及其可能机制。方法:以携带gankyrinsiRNA的慢病毒载体转染人胃癌细胞株MKN28,分别采用MTT实验、流式细胞术和蛋白质印迹法检测下调gankyrin表达对MKN28细胞增殖、细胞周期分布及其β-catenin/cyclinD1信号通路的影响。结果:慢病毒载体的转染效率在90%以上,转染gankyrinsiRNA后,MKN28细胞gankyrin蛋白表达显著受抑(P<0.01)。与未转染慢病毒和转染对照病毒的细胞相比,转染gankyrinsiRNA的MKN28细胞体外生长于第3天起显著受抑,细胞周期G1期细胞比率增高,S期细胞比率降低,细胞中的β-catenin和cyclinD1表达水平降低,差异均有统计学意义(P<0.01)。结论:下调胃癌细胞中的gankyrin表达可通过抑制β-catenin/cyclinD1信号通路引起细胞周期G1期阻滞和细胞增殖抑制,gankyrin有望成为胃癌靶向治疗的新靶点。